Journal
CLINICAL RHEUMATOLOGY
Volume 26, Issue 7, Pages 1186-1188Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-006-0325-z
Keywords
dermatomyositis; inflammatory myopathy; infliximab; polymyositis; tumor necrosis factor
Categories
Ask authors/readers for more resources
The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of initial treatment in the majority of cases of PM/DM. The treatment of refractory disease can be challenging despite the utilization of the medications currently available. We report two patients with refractory DM who were treated with infliximab. We describe their presentation, clinical course, treatment, and outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available